Dynamics of chronic myeloid leukaemia

Nature

Volumn 435, Issue 7046, 2005, Pages 1267-1270

  Michor, Franziska ^a   Hughes, Timothy P ^b   Iwasa, Yoh ^c   Branford, Susan ^b   Shah, Neil P ^d   Sawyers, Charles L ^d,e,f   Nowak, Martin A ^a  

^a HARVARD UNIVERSITY   (United States)

^b INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^c KYUSHU UNIVERSITY   (Japan)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC MYELOID LEUKAEMIA (CML); FOUR-COMPARTMENT MODEL; POLYMERASE CHAIN REACTIONS; STEM CELLS;

CELLS; DISEASES; ENZYME KINETICS; ENZYMES; MATHEMATICAL MODELS; MUTAGENESIS; ONCOLOGY;

TUMORS;

ABELSON KINASE; ENZYME INHIBITOR; IMATINIB;

CANCER;

ARTICLE; CELL COMPARTMENTALIZATION; CELL DIFFERENTIATION; CHRONIC MYELOID LEUKEMIA; COMPARTMENT MODEL; DYNAMICS; HEMATOPOIETIC SYSTEM; HUMAN; HUMAN CELL; LEUKEMIA CELL; MATHEMATICAL MODEL; PRIORITY JOURNAL; QUANTITATIVE ASSAY; STEM CELL;

CELL DIFFERENTIATION; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MODELS, BIOLOGICAL; PIPERAZINES; POINT MUTATION; PYRIMIDINES; RECURRENCE; RETROSPECTIVE STUDIES; STEM CELLS; TIME FACTORS; TREATMENT OUTCOME;

EID: 21744462100     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature03669     Document Type: Article

References (29)

1. Druker, B. J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Med. 2, 561-566 (1996).
2. Sawyers, C. L. et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99, 3530-3539 (2002).
3. Holtz, M. S. et al. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 99, 3792-3800 (2002).
4. Hughes, T. P. et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 349, 1423-1432 (2003).
5. Spangrude, G. J., Heimfeld, S. & Weissman, I. L. Purification and characterization of mouse hematopoietic stem cells. Science 241, 58-62 (1988).
6. Bhatia, R. et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101, 4701-4707 (2003).
7. Chu, S. et al. Detection of BCR-ABL kinase mutations in CD34 + cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 105, 2093-2098 (2005).
8. Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880 (2001).
9. Branford, S. et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Stood 99, 3472-3475 (2002).
10. Branford, S. et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102, 276-283 (2003).
11. Branford, S. et al. Real-time quantitative PCR analysis can be used as a primary screen to identify imatinib-treated patients with CML who have BCR-ABL kinase domain mutations. Blood 104, 2926-2932 (2004).
12. Hochhaus, A. et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16, 2190-2196 (2002).
13. Shah, N. P. et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117-125 (2002).
14. Roche-Lestienne, C. et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100, 1014-1018 (2002).
15. Roche-Lestienne, C., Lai, J. L., Darre, S., Facon, T. & Preudhomme, C. A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia. N. Engl. J. Med. 348, 2265-2266 (2003).
16. Branford, S., Hughes, T. P. & Rudzki, Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br. J. Haematol. 107, 587-599 (1999).
17. Cortes, J., O'Brien, S. & Kantarjian, H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 104, 2204-2205 (2004).
18. Higashi, T. et al. Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases. Am. J. Hematol. 76, 275-278 (2004).
19. Graham, S. M. et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99, 319-325 (2002).
20. Chaudhary, P. M. & Roninson, I. B. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66, 85-94 (1991).
21. Mahon, F. X. et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Stood 101, 2368-2373 (2003).
22. Branford, S. et al. The incidence of BCR-ABL kinase mutations in chronic myeloid leukemia patients is as high in the second year of imatinib therapy as the first but survival after mutation detection is significantly longer for patients with mutations detected in the second year of therapy. Blood 102, 414 (2003)
23. Kunkel, T. A. & Bebenek, K. DNA replication fidelity. Annu. Rev. Biochem. 69, 497-529 (2000).
24. Holyoake, T. L., Jiang, X., Drummond, M. W., Eaves, A. C. & Eaves, C. J. Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia. Leukemia 16, 549-558 (2002).
25. Holyoake, T., Jiang, X., Eaves, C. & Eaves, A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 94, 2056-2064 (1999).
26. Mahon, F. X. et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101, 2368-2373 (2003).
27. Chaudhary, P. M. & Roninson, I. B. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66, 85 (1991).
28. Bedi, A. et al. BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia. Blood 81, 2898-28902 (1993).
29. Shah, N. P. et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399-401 (2004).